Published on September 9, 2009 at 7:51 AM
Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced that Dr. Fahar Merchant, President & CEO of Protox Therapeutics, will present at the 11th Annual Rodman & Renshaw Healthcare Conference. The conference runs from Wednesday, September 9 through Friday, September 11 at the Palace Hotel in New York City. Dr. Merchant's presentation is at 9:10 a.m. ET on Friday, September 11 in the Garrison Salon on the 5th floor of the hotel and will be webcast live from Protox's website.
Dr. Merchant will present the corporate story and upcoming milestone highlights, including an update on TRIUMPH, a double-blinded placebo controlled Phase 2b study of PRX302 in patients with benign prostatic hyperplasia (BPH). Dr. Merchant will also be presenting 12-month data from the Phase 2a open-label BPH study.
Source: PROTOX THERAPEUTICS INC.